(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 December 2015 (10.12.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/186988 A1

(51) International Patent Classification:
C07K 16/46 (2006.01) *A61P 37/06* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/KR2015/005651

(22) International Filing Date:
5 June 2015 (05.06.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10-2014-0068660 5 June 2014 (05.06.2014) KR

(71) Applicant: **HANMI PHARM. CO., LTD.** [KR/KR]; 214, Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do 445-958 (KR).

(72) Inventors: **PARK, Sung Hee**; 603-1804, 209, Pangyo-won-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-959 (KR). **KIM, Seung Su**; 1501, 45, Seochojungang-ro, Seocho-gu, Seoul 137-953 (KR). **LIM, Hyung Kyu**; 757-703, 315-18, Dongtanwoncheon-ro, Hwaseong-si, Gyeonggi-do 445-996 (KR). **CHOI, Jae Hyuk**; 106-1602, 446, Hangaram-ro, Songpa-gu, Seoul 138-780 (KR). **CHOI, In Young**; 105-1801, 70, Yonggu-daero 2771beon-gil, Suji-gu, Yongin-si, Gyeonggi-do 448-160 (KR). **KWON, Se Chang**; 408-1804, 221, Seolleung-ro, Gangnam-gu, Seoul 135-506 (KR).

(74) Agent: **SON, Min**; Hanol Intellectual Property&Law, STX R&D Center, 6th Floor, 163, YangJaeCheon-ro, Gangnam-gu, Seoul 135-855 (KR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: METHOD FOR DECREASING IMMUNOGENICITY OF PROTEIN AND PEPTIDE



(57) Abstract: The present invention relates to a method for increasing serum half-life of a protein or peptide and decreasing immunogenicity thereof by site-specifically binding a carrier to a protein or peptide, and to the use thereof. The conjugate of the physiologically active protein or peptide of the present invention can significantly decrease immunogenicity in the human body and thus reduce antibody production rate against the protein or peptide. Therefore, the present conjugate has advantages in that a phenomenon of reduced clinical effects of the physiologically active protein or peptide is low, and it can be effectively used in the development of long-acting formulations having a high safety against the immune response.

WO 2015/186988 A1

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*